Journal of Clinical Lipidology
Volume 3, Issue 2 , Pages 138-142 , April 2009

Ezetimibe, and the combination of ezetimibe/simvastatin, and risk of cancer: A post-marketing analysis

  • Alawi A. Alsheikh-Ali, MD

      Affiliations

    • Institute for Clinical Research and Health Policy Studies, Tufts Medical Center and Tufts University School of Medicine, 800 Washington St, Box #80, Boston, MA 02111USA
    • Molecular Cardiology Research Institute, Department of Medicine, Tufts Medical Center and Tufts University School of Medicine, 800 Washington St, Boston, MA 02111USA
    • ,
  • Richard H. Karas, MD, PhD

      Affiliations

    • Molecular Cardiology Research Institute, Department of Medicine, Tufts Medical Center and Tufts University School of Medicine, 800 Washington St, Boston, MA 02111USA
    • Corresponding Author InformationCorresponding author.

Received 13 November 2008 ,Accepted 8 February 2009.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

PII: S1933-2874(09)00080-4

doi: 10.1016/j.jacl.2009.02.005

Journal of Clinical Lipidology
Volume 3, Issue 2 , Pages 138-142 , April 2009

Article Tools

* Image Usage & Resolution